LONDON (Alliance News) - Avacta Group PLC on Thursday said it has received a positive set of results on the first pre-clinical studies of its Affimer molecules.
The results demonstrated good pharmacokinetic properties, with no adverse effects observed, Avacta said. It said the results confirm the potential of its Affimer biotherapeutics and research re-agents as a therapeutic platform.
"These results demonstrate that Affimer molecules possess good in-vivo drug-like properties in terms of efficacy, serum half-life and tolerability which is a hugely important milestone in the development and de-risking of the technology as a therapeutic platform," said Avacta Chief Executive Alastair Smith.
Shares in Avacta were up 5.3% at 103.75 pence on the news.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)